Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Curcumin** is a plant-derived polyphenolic diarylheptanoid and the principal curcuminoid found in turmeric, the rhizome of *Curcuma longa*. It is a chemically defined small molecule rather than turmeric powder or a mixed curcuminoid extract. Curcumin has been widely studied as an oral nutraceutical and investigational therapeutic for metabolic disorders, inflammatory diseases, fatty liver disease, depression, cancer supportive care, and cancer cachexia. It has low intrinsic oral bioavailability because of limited absorption and rapid metabolism and elimination; many clinical studies therefore use enhanced-bioavailability formulations, which are distinct products from unformulated curcumin. ([pubchem.ncbi.nlm.nih.gov](https://pubchem.ncbi.nlm.nih.gov/compound/Curcumin)) Its pharmacology is pleiotropic, with reported suppression of inflammatory signaling including NF-kappa B pathways and modulation of oxidative-stress responses, but no single clinically validated primary molecular target has been established. Curcumin is sold predominantly as a dietary supplement and is not an approved pharmaceutical treatment for the diseases listed here. ([nccih.nih.gov](https://www.nccih.nih.gov/health/turmeric?here%E2%80%99s_what_to_expect=))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on curcumin.